Zymeworks ZYME Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research and development collaborations by Product | ||||||
| Development support payments | $1.52M-73.0% | $5.62M— | —— | —— | —— | |
| Drug supply for ongoing studies | $3.94M-39.9% | $6.55M-31.3% | $9.53M-31.1% | $13.83M-13.4% | $15.97M-17.0% | |
| Other drug supply | $195K-91.2% | $2.23M-48.6% | $4.34M-57.9% | $10.3M-35.8% | $16.04M+3.7% | |
| Royalties | $3.61M+45.5% | $2.48M+47.4% | $1.68M+97.5% | $852K+182% | $302K+202% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Zymeworks break its business down?
- Zymeworks (ZYME) reports research and development collaborations by product across 5 parts — Development support payments, Drug supply for ongoing studies, Milestone revenue, Other drug supply and Royalties. Each is extracted from the segment footnotes and tracked over time.
- Where does Zymeworks's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Zymeworks's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
